Monte Rosa Therapeutics has shared positive interim data from an ongoing Phase I clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1, and IL-6. “These remarkable interim data from our ongoing Phase I study of… Read More
MetaVia has announced positive statistically significant results from the eight-week, non-titrated 48mg, multiple ascending dose (MAD) cohort of its Phase I clinical trial of DA-1726. DA-1726 is a novel, dual oxyntomodulin (OXM) analogue agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for… Read More
The US Food and Drug Administration (FDA) has cleared GenEditBio to initiate Phase I/II CLARITY trial activities for its lead in vivo genome-editing programme GEB-101 for TGFBI corneal dystrophy. The Phase 1/2 CLARITY trial will collect initial data on the safety, tolerability and efficacy of GEB-101 in corneal dystrophy patients… Read More
Scarcell Therapeutics has treated the first patients with its allogenic gingival fibroblast (aGF) therapy using gum cells from a human donor as part of its Phase Ib clinical trial studying the therapy in knee osteoarthritis (OA). The first-in-human cases took place at Oxford University Hospitals, UK, and… Read More
Pyxis Oncology has announced positive preliminary data from its ongoing Phase I clinical studies evaluating micvotabart pelidotin (MICVO) in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). MICVO is an antibody-drug conjugate (ADC) targeting extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the… Read More
Avacta Therapeutics has announced new data in patients with salivary gland cancer (SGC) enrolled in the ongoing Phase Ib trial of faridoxorubicin (AVA6000). The data show confirmed partial and minor responses, consistent with data previously reported from the Phase Ia part of the study. … Read More
A world-first clinical trial is launching to test an experimental vaccine designed to prevent lung cancer in people at high risk of the disease. Lung cancer remains the leading cause of cancer death in the UK, accounting for 20% of cancer deaths each year. Researchers… Read More
CRISPR Therapeutics has shared positive Phase I data from an ongoing clinical trial evaluating CTX310, an investigational, in vivo CRISPR/Cas9 gene-editing therapy targeting ANGPTL3. A single-course treatment with CTX310 produced dose-dependent, durable reductions in circulating ANGPTL3 with a mean reduction from baseline of -73% (maximum… Read More
Celldex has revealed positive data from the ongoing Phase I study of CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosis. These pathways are mast cell depletion via stem cell factor (SCF) starvation and neutralisation of the alarmin thymic stromal… Read More
Cambritaxestat, a treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC), has met its primary endpoint in a Phase Ib trial. Cambritaxestat, an oral autotaxin (ATX) inhibitor, was evaluated in patients with previously untreated mPDAC. The treatment demonstrated safety, tolerability and anti-tumour responses, with data presented at the European Society… Read More
A number of key clinical and preclinical study results into potential Parkinson’s disease (PD) therapeutics were announced at the International Congress of Parkinson’s Disease and Movement Disorders. Unexpected early results for allosteric enzyme modulator Gain Therapeutics shared encouraging early results from the Phase Ib clinical study of GT-02287 in people… Read More
Gain Therapeutics has shared early safety and tolerability findings, the primary endpoint, and observations from key exploratory endpoints from the Phase Ib clinical study of GT-02287 in people with Parkinson’s disease (PD) with or without a GBA1 mutation. The findings were presented in a poster at the… Read More
Biopharmaceutical company Seaport Therapeutics has announced that the first patient has been dosed in a Phase I clinical trial of its treatment for generalised anxiety disorder. Seaport’s GlyphAgo is an oral prodrug of agomelatine, which is a clinically validated melatonin receptor agonist and serotonin 2C receptor antagonist. Read More
Purespring Therapeutics’ UK Clinical Trial Application (CTA) for a planned Phase I/II study of PS-002 in patients with IgA nephropathy (IgAN) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the NHS Health Research Authority (HRA) and Research Ethics Committee (REC). PS-002 was developed to target… Read More
A Phase I clinical trial of CD40 agonist antibody 2141-V11 has shown positive results, with six patients seeing their tumours shrink. CD40 is a cell surface receptor and member of the tumour necrosis factor (TNF) receptor superfamily, proteins that are largely expressed by immune cells. … Read More
In a Phase I trial, single-agent CD19 CAR-NK natural killer cell therapy has achieved complete responses in two patients with third-line Waldenstrom macroglobulinemia (WM), a type of non-Hodgkins lymphoma (NHL). QUILT-106 is a first-in-human trial evaluating the safety and preliminary efficacy of CD19 CAR-NK cell therapy alone… Read More
